Research advances in cellular immunotherapy for primary hepatocellular carcinoma
10.3969/j.issn.1001-5256.2014.09.006
- VernacularTitle:肝细胞癌细胞免疫治疗的研究进展
- Author:
Ye ZHANG
;
Mingjie ZHANG
;
Zhansheng JIA
- Publication Type:Journal Article
- Keywords:
carcinoma,hepatocellular;
immunotherapy,active;
immunotherapy,adoptive;
review
- From:
Journal of Clinical Hepatology
2014;30(9):860-864
- CountryChina
- Language:Chinese
-
Abstract:
The present therapy for primary hepatocellular carcinoma (HCC)consists of surgery as well as local radiotherapy and chemother-apy.However,the majority of patients are susceptible to recurrence after comprehensive treatment,and the overall treatment outcome is not ideal due to the lack of effective drugs and strategies.Increasing evidence has demonstrated that the immune system is closely related to the development,progression,metastasis,and recurrence of HCC.Thus,immune therapy,especially cellular immunotherapy,could regulate immune function and induce specific antitumor immunity to achieve the goal of controlling HCC and reducing its recurrence and metastasis, which has become an essential part in the comprehensive treatment of HCC.The findings in preclinical and clinical studies on cellular immu-notherapy for HCC data are reviewed,and the current problems are discussed.
